Brokerages Expect Haemonetics Co. (NYSE:HAE) Will Post Earnings of $0.60 Per Share

Analysts forecast that Haemonetics Co. (NYSE:HAEGet Rating) will report earnings of $0.60 per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Haemonetics’ earnings, with the highest EPS estimate coming in at $0.62 and the lowest estimate coming in at $0.57. Haemonetics reported earnings of $0.46 per share in the same quarter last year, which would indicate a positive year over year growth rate of 30.4%. The firm is expected to issue its next earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Haemonetics will report full year earnings of $2.53 per share for the current fiscal year, with EPS estimates ranging from $2.50 to $2.55. For the next fiscal year, analysts anticipate that the company will report earnings of $2.76 per share, with EPS estimates ranging from $2.55 to $3.05. Zacks’ EPS averages are an average based on a survey of analysts that follow Haemonetics.

Haemonetics (NYSE:HAEGet Rating) last released its quarterly earnings results on Tuesday, February 8th. The medical instruments supplier reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.09. The company had revenue of $259.77 million during the quarter, compared to the consensus estimate of $265.40 million. Haemonetics had a return on equity of 17.33% and a net margin of 2.37%. Haemonetics’s revenue was up 8.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.81 earnings per share.

Several equities research analysts have recently issued reports on the company. Raymond James decreased their price objective on Haemonetics from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Wednesday, February 9th. StockNews.com assumed coverage on Haemonetics in a report on Thursday, March 31st. They set a “hold” rating on the stock. Barrington Research restated an “outperform” rating on shares of Haemonetics in a report on Wednesday, February 9th. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a report on Thursday, January 27th. Finally, Morgan Stanley decreased their price objective on Haemonetics from $68.00 to $60.00 and set an “equal weight” rating on the stock in a report on Friday, January 7th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics currently has a consensus rating of “Buy” and an average target price of $71.67.

A number of large investors have recently added to or reduced their stakes in HAE. BlackRock Inc. raised its position in Haemonetics by 16.9% in the third quarter. BlackRock Inc. now owns 6,990,542 shares of the medical instruments supplier’s stock valued at $493,464,000 after purchasing an additional 1,011,239 shares during the period. Capital Research Global Investors raised its position in Haemonetics by 80.7% in the fourth quarter. Capital Research Global Investors now owns 2,049,133 shares of the medical instruments supplier’s stock valued at $108,686,000 after purchasing an additional 915,385 shares during the period. Wellington Management Group LLP raised its position in Haemonetics by 15.0% in the third quarter. Wellington Management Group LLP now owns 4,244,307 shares of the medical instruments supplier’s stock valued at $299,606,000 after purchasing an additional 553,118 shares during the period. Janus Henderson Group PLC raised its position in Haemonetics by 74.1% in the third quarter. Janus Henderson Group PLC now owns 1,204,684 shares of the medical instruments supplier’s stock valued at $85,039,000 after purchasing an additional 512,612 shares during the period. Finally, River Road Asset Management LLC raised its position in Haemonetics by 94.6% in the fourth quarter. River Road Asset Management LLC now owns 795,700 shares of the medical instruments supplier’s stock valued at $42,204,000 after purchasing an additional 386,813 shares during the period. 98.65% of the stock is currently owned by institutional investors.

Haemonetics stock traded down $0.86 during mid-day trading on Monday, hitting $56.82. 349,200 shares of the company were exchanged, compared to its average volume of 442,063. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.05 and a quick ratio of 1.19. The business’s 50 day simple moving average is $57.80 and its two-hundred day simple moving average is $57.73. The company has a market capitalization of $2.90 billion, a P/E ratio of 132.14, a PEG ratio of 2.06 and a beta of 0.30. Haemonetics has a 12-month low of $43.50 and a 12-month high of $119.53.

Haemonetics Company Profile (Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.

Further Reading

Get a free copy of the Zacks research report on Haemonetics (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.